Abliva AB (Germany) Today
| NTP Stock | EUR 0.03 0.0009 2.89% |
PerformanceGood
| Odds Of DistressHigh
|
Abliva AB is trading at 0.0302 as of the 7th of March 2025. This is a 2.89% down since the beginning of the trading day. The stock's lowest day price was 0.0302. Abliva AB has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 5th of February 2025 and ending today, the 7th of March 2025. Click here to learn more.
NeuroVive Pharmaceutical AB engages in the research and development of mitochondrial medicine in Sweden and internationally. NeuroVive Pharmaceutical AB was founded in 2000 and is headquartered in Lund, Sweden. NeuroVive Pharmaceutical operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. The company has 1.06 B outstanding shares. More on Abliva AB
Moving together with Abliva Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Abliva Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Abliva AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Abliva AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CFO CEO | Catharina Johansson |
| Business Concentration | Drug Manufacturers - Major, Healthcare (View all Sectors) |
Abliva AB (NTP) is traded on Frankfurt Exchange in Germany and employs 8 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.32 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abliva AB's market, we take the total number of its shares issued and multiply it by Abliva AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Abliva AB classifies itself under Healthcare sector and is part of Drug Manufacturers - Major industry. The entity has 1.06 B outstanding shares.
Abliva AB has accumulated about 5.84 M in cash with (114.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Abliva AB Probability Of Bankruptcy
Ownership AllocationAbliva AB holds a total of 1.06 Billion outstanding shares. 30% of Abliva AB outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Abliva Ownership Details
Abliva AB Risk Profiles
Although Abliva AB's alpha and beta are two of the key measurements used to evaluate Abliva AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 29.44 | |||
| Semi Deviation | 18.73 | |||
| Standard Deviation | 67.87 | |||
| Variance | 4605.9 |
Abliva Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Abliva AB without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Abliva AB Corporate Management
Elected by the shareholders, the Abliva AB's board of directors comprises two types of representatives: Abliva AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abliva. The board's role is to monitor Abliva AB's management team and ensure that shareholders' interests are well served. Abliva AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abliva AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lars Vedin | Consultant | Profile | |
| Magnus Hansson | Chief Medical Officer | Profile | |
| Eskil Elmr | Chief Discovery | Profile | |
| Ellen Donnelly | Chief Officer | Profile |
Other Information on Investing in Abliva Stock
Abliva AB financial ratios help investors to determine whether Abliva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abliva with respect to the benefits of owning Abliva AB security.